Stocktoria
TriSalus Life Sciences, Inc. TLSI
TriSalus Life Sciences, Inc. (TLSI) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $45.2M at a -86.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TLSI | TriSalus Life Sciences, Inc. | 4/9 | — | — | +53.4% |
| SNWV | SANUWAVE Health, Inc. | 6/9 | -19.06 | 6.3 | +35% |
| SI | SHOULDER INNOVATIONS, INC. | 4/9 | 7.68 | — | +49.6% |
| SSII | SS Innovations International, Inc. | 4/9 | -0.09 | — | +105.7% |
| KRMD | KORU Medical Systems, Inc. | 4/9 | -0.06 | — | +22.2% |
| CARL | CARLSMED, INC. | 5/9 | 4.88 | — | +85.9% |
| IDXG | INTERPACE BIOSCIENCES, INC. | 4/9 | -16.52 | 1.9 | -17.5% |
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
FAQ
Is TLSI financially healthy?
TriSalus Life Sciences, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does TLSI pay a dividend?
No, TriSalus Life Sciences, Inc. does not currently pay a dividend.
How profitable is TLSI?
In FY2025, TriSalus Life Sciences, Inc. had a net margin of -86.9%.
What is the analyst price target for TLSI?
The average Wall-Street price target for TriSalus Life Sciences, Inc. is $8.80, about 54.1% above the recent price, from 5 analysts (consensus: strong buy).
Is TLSI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on TriSalus Life Sciences, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.